PHILADELPHIA – A third phase 3 trial with the novel lipid-lowering drug inclisiran (The Medicines Company), which is given just once every 6 months, has shown impressive results in reducing in ...

PHILADELPHIA — A second phase 3 trial with the novel lipid-lowering agent inclisiran (The Medicines Company), which is administered just twice yearly as a subcutaneous injection, have shown impressive ...

Prolonged exposure to inclisiran (Leqvio; Novartis), the small-interfering RNA therapy (siRNA) that lowers LDL-cholesterol levels, is safe and well tolerated in a wide group of patients with ...

MIAMI--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced interim results from the ongoing ORION-3 open-label extension study (Group 1, n=290) which showed that twice-a-year dosing ...

FDA finally approved inclisiran (Leqvio), making it the first small interfering RNA (siRNA) therapy to hit the market for reducing LDL cholesterol, Novartis announced on Wednesday. The PCSK9 inhibitor ...

Longer-term follow-up of high-risk patients treated with inclisiran (Leqvio; Novartis) shows that the early reductions in LDL-cholesterol levels are sustained over several years, according to results ...

PHILADELPHIA--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced detailed results from ORION-10, the second of three pivotal 18-month low-density lipoprotein cholesterol (LDL-C) ...

Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin–kexin type 9. Previous studies suggest that inclisiran might provide sustained reductions in low-density lipoprotein (LDL) ...

The Medicines Company has posted more late-phase data (PDF) linking its siRNA inclisiran to steep declines in LDL cholesterol. Inclisiran achieved a placebo-adjusted drop in LDL cholesterol of 58%, ...